[1]SCHWEITZER A,HORJ J,MIKOLAJCZYK RT,et al.Estimations o worldwide prevalence of chronic hepatitis B virus infection:a systematic review of data published between 1965 and 2013[J].Lancet,2015,386(10003):1546-1555.
|
[2]BLANKSON A,WIREDU EK,ADJEI A,et al.Seroprevalence of hepatitis B and C viruses in cirrhosis of the liver in Accra,Ghana[J].Ghana Med J,2005,39(4):132-137.
|
[3]FONTANA RJ.Management of patients with decompensated HBVcirrhosis[J].Semin Liver Dis,2003,23(1):89-100.
|
[4]MARCELLIN P,ASSELAH T,BOYE N.Fibrosis and disease progression in hepatitis C[J].Hepatol,2002,36(5):47-56.
|
[5]XU MY,WANGY,LU LG,et al.Relationship of differential gene expression profiles to HBV-related fibrogenesis and carcinogenesis[J].J Hepatol,2012,56(2):415-416.
|
[6]XU MY,QU Y,LU LG,et al.Genomic profile and functiona characterization of fibrosis in patients with chronic hepatitis B[J].JHepatol,2013,18(7):435-438.
|
[7] Chinese Society of Hepatology,Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline for prevention and treatment of chronic hepatitis B[J].J Chin Hepatol,2006,22(1):3-15.(in Chinese)中华医学合肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南[J].临床肝胆病杂志,2006,22(1):3-15.
|
[8] Experts in combined team of the major specialproject of ministry of sciences and technology supported by China's“twelfth of five-year plan”.Management of clinical diagnosis,evaluation,and antiviral therapy fo HBV-related cirrhosis[J].Chin J Hepatol,2014,22(2):327-335.(in Chinese)科技部十二五重大专项联合课题组.乙型肝炎病毒相关肝硬化的临床诊断﹑评估和抗病毒治疗的综合管理[J].中华肝脏病杂志,2014,22(2):327-335.
|
[9]WANG FS,FAN JG,ZHANG Z,et al.The global burden of live disease:the major impact of China[J].Hepatology,2014,60(6):2099-2108.
|
[10]SARIN SK,KUMAR M,LAU GK,et al.Asian-Pacific clinica practice guidelines on the management of hepatitis B:a 2015 update[J].Hepatol Int,2016,10(1):1-98.
|
[11]LIAW YF.Impact of therapy on the long-term outcome of chronic hepatitis B[J].Clin Liver Dis,2013,17(3):413-423.
|
[12]ZOUTENDIJK R,REIJNDERS JG,ZOULIM F,et al.Virologica response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis[J].Gut,2013,62(5):760-765.
|
[13]LI DL,ZHENG LH,JIN L,et al.CD24 polymorphisms affect risk and progression of chronic hepatitis B virus infection[J].Hepatol,2009,50(3):735-742.
|
[14]ZHANG J,JIAO J,CERMELLI S,et al.miR-21 inhibition reduces liver fibrosis and prevents tumor development by inducing apoptosis of CD24+progenitor cells[J].Cancer Res,2015,75(9):1859-1867.
|
[15]DOMINGUEZ M,MIQUEL R,COLMENERO J,et al.Hepatic expression of CXC chemokines predicts portal hypertension and survival in patients with alcoholic hepatitis[J].Gastroenterology,2009,136(5):1639-1650.
|
[16]PRITCHETT J,HARVEY E,ATHWAL V,et al.Osteopontin is a novel downstream target of SOX9 with diagnostic implications for progression of liver fibrosis in humans[J].Hepatol,2012,56(3):1108-1116.
|
[17]PRITCHETT J,ATHWAL VS,HARVEY E,et al.Epimorphin alters the inhibitory effects of SOX9 on MMP13 in activated hepatic stellate cells[J].PLoS One,2014,9(6):e100091.
|
[18]KRISHNAN A,LI X,KAO WY,et al.Lumican,an extracellular matrix proteoglycan,is a novel requisite for hepatic fibrosis[J].Lab Invest,2012,92(12):1712-1725.
|
[19]PILLING D,VAKIL V,COX N,et al.TNF-α-stimulated fibroblasts secrete lumican to promote fibrocyte differentiation[J].Proc Natl Acad Sci USA,2015,112(38):11929-11934.
|